The growing prevalence of neurological conditions globally due to rising geriatric population and increasing lifestyle-related risk factors is driving the need for effective treatment options. Several gene and cell therapy candidates are under clinical evaluation for various CNS targets and may receive regulatory approvals over the forecast period. Additionally, active research to understand the molecular basis of brain disorders and identify new therapeutic targets will further support market growth.

Market drivers

One of the key drivers for the Gene And Cell Therapies Targeting CNS Disorders Market Demand is the rising investment by both private and public organizations in neuroscience research. According to data, global spending on neuroscience R&D increased from $6 billion in 1990 to $180 billion in 2020 and is expected to surpass $300 billion by 2025. This has enabled major advancements in understanding the pathophysiology of brain disorders and developing novel biological treatment approaches. Increased R&D funding is facilitating drug discovery, preclinical and clinical testing of numerous pipeline candidates, which will expand lucrative market opportunities over the coming years.

The geopolitical situation is impacting the growth of the Gene and Cell Therapies Targeting CNS Disorders Market. With rising political tensions and global instability, there are concerns about cross-border collaborations and regulatory approvals being delayed. Resource allocation is also getting affected as governments focus on challenges like healthcare reforms and economic recovery in the post-pandemic period. However, this market still holds immense potential given the high prevalence of CNS disorders and lack of effective treatment options currently. By focusing on domestic collaborations, streamlining approval processes, and increasing advocacy for CNS research funding, companies can help accelerate product development and commercialization. Partnering with local clinical sites and leveraging virtual platforms can aid international trials as well. As the geopolitical climate stabilizes in the coming years, this market is set to realize its full growth potential through strengthened multilateral cooperation and policy support for neurological disease management.

North America currently accounts for the largest share of the Gene and Cell Therapies Targeting CNS Disorders Market in terms of value. This can be attributed to factors like the rising healthcare spending, presence of advanced research infrastructure and global industry leaders, as well as supportive regulatory environment for novel therapy approvals in the region. Meanwhile, Asia Pacific is poised to emerge as the fastest growing regional market owing to the surge in clinical trials, growing geriatric population, increasing investments in biotechnology and life sciences sectors by governments as well as private players across countries like China and India.

Get more insights, On Gene And Cell Therapies Targeting CNS Disorders Market